Evidence map›Paper›PMID 39409039›Full record

ArticleInternational journal of molecular sciences2024

Characterization and Hemocompatibility of α, β, and γ Cyclodextrin-Modified Magnetic Nano-Adsorbents.

Mehdi Ghaffari Sharaf, Shuhui Li, Elyn M Rowe, Dana V Devine, Larry D Unsworth

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mehdi Ghaffari SharafDepartment of Chemical and Materials Engineering, University of Alberta, Edmonton, AB T6G 1H9, Canada.ORCID 0000-0003-1285-8533
Shuhui LiDepartment of Chemical and Materials Engineering, University of Alberta, Edmonton, AB T6G 1H9, Canada.ORCID 0000-0002-1034-8831
Elyn M RoweDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 1Z7, Canada.
Dana V DevineDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 1Z7, Canada.ORCID 0000-0002-9059-0344
Larry D UnsworthDepartment of Chemical and Materials Engineering, University of Alberta, Edmonton, AB T6G 1H9, Canada.ORCID 0000-0003-3162-3545

Funding

Alberta Innovates-Alliance from Canada 222300464Alberta Innovates-Strategic Research Project from Canada 222300346
6 · The paper itself

Abstract

Kidney dysfunction leads to the retention of metabolites within the blood that are not effectively cleared with conventional hemodialysis. Magnetic nanoparticle (MNP)-based absorbents have inherent properties that make them amenable to capturing toxins in the blood, notably a large surface area that can be chemically modified to enhance toxin capture and the ability to be easily collected from the blood using an external magnetic field. Cyclodextrins (CDs) present a chemical structure that facilitates the binding of small molecules. However, the hemocompatibility of MNPs modified with films composed of different native types of CDs (α, β, or γ) has not yet been investigated, which is information crucial to the potential clinical application of MNPs to supplement hemodialysis. To this end, films of α-, β-, or γ-CDs were formed on MNPs and characterized. The impact of these films on the adsorbed protein structure, composition of key adsorbed proteins, and clotting kinetics were evaluated. It was found that modified MNPs did not significantly affect the secondary structure of some proteins (albumin, lysozyme, α-lactalbumin). The adsorbed proteome from platelet-poor human plasma was evaluated as a function of film properties. Compared to non-modified nanoparticles, CD-modified MNPs exhibited a significant decrease in the adsorbed protein per surface area of MNPs. The immunoblot results showed variations in the adsorption levels of C3, fibrinogen, antithrombin, Factor XI, and plasminogen across CD-modified MNPs. The hemocompatibility experiments showed that CD-modified MNPs are compatible with human whole blood, with no significant impact on platelet activation, hemolysis, or hemostasis.

Indexed as

Magnetite NanoparticlesAdsorptionalpha-Cyclodextrinsbeta-CyclodextrinsBiocompatible MaterialsBlood CoagulationCyclodextrinsgamma-CyclodextrinsHumansMaterials Testingalpha-Cyclodextrinsbeta-CyclodextrinsBiocompatible MaterialsCyclodextrinsgamma-CyclodextrinsMagnetite Nanoparticlesadsorbentchronic kidney diseasecyclodextrinhemocompatibilitymagnetic nanoparticleprotein adsorptionuremic toxin

Identifiers

PMID39409039
PMCPMC11476827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.